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Abstract
Objectives. Evidence suggests that factors beyond disease activity associate with functional disability in RA. The
primary study objective was to explore associations between comorbidities, sociodemographic factors and func-
tional outcomes at five and 10 years.
Methods. RA patients from two UK prospective cohorts were grouped into low (<1.5) and high (1.5) five- and
10-year health assessment questionnaire (HAQ) score. Clinical variables (e.g. disease activity, rheumatoid nodules,
erosions) and sociodemographic factors (e.g. ethnicity, deprivation) were recorded at baseline and yearly thereafter.
Comorbidity was measured using the Rheumatic Diseases Comorbidity Index (RDCI). Binary logistic regression
models were fitted using multiple imputation.
Results. In total, 2701 RA patients were recruited (mean age 56.1 years, 66.9% female). A total of 1718 (63.4%)
had five-year and 820 (30.4%) 10-year follow-up data. In multivariable analysis, no association was found between
RDCI and HAQ 1.5 at five or 10 years. Sociodemographic factors (increased age at disease onset, female gender,
minority ethnicity) were associated with higher odds of HAQ1.5 at five and 10 years, with worse deprivation add-
itionally associated with HAQ1.5 at 10 years (OR 0.79, 95% CI: 0.69, 0.90).
Conclusion. Comorbidities at baseline have not been found to be associated with worse RA functional outcome
in the long-term. On the other hand, sociodemographic factors, independently of disease measures, are associated
with worse functional outcome in RA at five and 10 years, in models adjusting for comorbidity burden. Tailoring
management interventions according to not only clinical disease parameters but also patient sociodemographic fac-
tors may improve long-term outcomes including functional disability.
Key words: sociodemographic factors, comorbidity, multimorbidity, Health Assessment Questionnaire,
rheumatoid arthritis
Introduction
Functional disability in RA is a well-recognised and his-
torically reported debilitating outcome of disease,
adding significantly to the overall global burden of RA
[1]. Worsening functional ability in RA has been linked to
the ongoing, progressive course of this chronic, inflam-
matory musculoskeletal condition and comes at both
physical and psychological cost to patients. Indeed,
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functional measures are often used as a substitute for
quality of life in RA [2].
Generally, it is accepted that poor disease control
negatively impacts functional ability, especially in early
disease, but some studies have shown this is not always
the case. Functional deterioration has been reported in
10–21% of early RA patients with moderate disease ac-
tivity when following standard treatment [3]. Beyond in-
flammation, other factors that may cause worse function
need to be considered.
The comorbidity burden in RA is substantial, even on
first presentation of disease [4]. Yet, this observation
does not seem to be accompanied by increasing dis-
ease severity, whether measured by markers of high dis-
ease activity or worse physical function [4]. Additionally,
the presence of comorbidities has been associated with
unfavourable functional and disease activity outcomes
over two years, despite intensive treatment strategies
aiming for remission [5]. Disentangling the underlying
mechanisms and understanding potential causal links
between comorbidities and disease outcomes including
function in RA is challenging. Associations between
comorbidities and poor health outcomes including phys-
ical disability have been traditionally studied alongside
other disease-related factors, e.g. inflammation, but not
in relation to non-biological, sociodemographic factors.
Sociodemographic determinants of health play a cru-
cial role in health and disease and have gained much at-
tention in recent times, where there is an expectation to
manage patients more holistically, with care tailored to
their individual physical and psychosocial needs. To
achieve this, we have argued for a better understanding
of the role of sociodemographic factors, alongside im-
portant clinical factors including comorbidities, as driv-
ers of adverse outcomes in RA [6]. In seeking to unravel
these so-called ‘syndemic’ elements [6], this study
stems from a larger research initiative to understand
multimorbidity in the disease and risk-stratify patients
according to individual need .
The aim was to identify predictors of worse five- and
10-year functional outcome, measured using the HAQ,
using information available at first outpatient appointment.
Of particular interest was whether patients affected by
comorbidities have an elevated risk of poor functional
ability, taking into account sociodemographic factors.
Methods
Study population
This study used data collected within the Early RA Study
(ERAS, 1986–2001) and Early RA Network (ERAN, 2002–
2012). These are consecutive prospective cohorts,
designed similarly regarding recruitment, variables col-
lected and follow-up timings, often studied together and
previously described in detail [7]. ERAS patients were
recruited from nine hospitals in England and ERAN
patients from 23 centres across England, Wales and
Northern Ireland. Dates of deaths occurring in the UK
were reported by NHS Digital for all participants who con-
sented to follow-up. ERAS patients gave informed con-
sent as required at time of enrolment [prior to Good
Clinical Practice (GCP) implementation], approved by the
East Hertfordshire Local Research Ethics Committee.
ERAN patients gave informed, written consent, approved
by the Trent Research Ethics Committee .
Baseline measures
Comorbidities
The variable of interest was baseline comorbidity, meas-
ured using the Rheumatic Disease Comorbidity Index
(RDCI [8]). Scores ranged from 0 to 9, where higher
scores indicated a higher comorbidity burden, and were
used as a continuous variable in the analysis. The RDCI
arranges 11 illness types into eight categories (lung dis-
ease, heart attack/other cardiovascular/stroke), fracture,
depression, cancer, ulcer/stomach problem, hyperten-
sion, diabetes), defined using International Classification
of Diseases, Ninth Revision, Clinical Modification (ICD-9-
CM) codes. As well as overall RDCI values, individual
disease categories were assessed to determine associ-
ation with high HAQ outcome.
Sociodemographic and clinical variables
At baseline, standard demographic data were recorded
including age at onset, gender and ethnicity. Patient
postcodes were used to derive an Index of Multiple
Deprivation [9] (IMD), Welsh Index of Multiple Deprivation
[10] (WIMD) or Northern Ireland Multiple Deprivation
Measure [11] (NIMDM) rank, then grouped into quintiles
to enable comparison across regions. Clinical data col-
lected at each appointment included HAQ, BMI, haemo-
globin, ESR and presence of erosions, rheumatoid
nodules, RF and anti-cyclic citrullinated peptide autoanti-
bodies (anti-CCP). Disease activity was measured using
the 28-joint Disease Activity Score DAS28 [12] for ERAN
and the Disease Activity Score (DAS [13]) in the ERAS co-
hort. DAS scores were transformed so they could be dir-
ectly comparable to the DAS28 using a formula
previously tested and applied on the same data
(Carpenter et al. [14]). Months from onset of symptoms to
first rheumatology outpatient appointment and from first
appointment to prescription of the first DMARD were
each recorded. Variables were continuous (e.g. age,
haemoglobin, ESR) or categorical, e.g. IMD (quintiles; 1,
most deprived to 5, least deprived), smoking status (ever/
never), serostatus (positive/negative RF and/or anti-CCP),
ethnicity (white/minority ethnic).
Outcome measures
Five-year and 10-year HAQ
HAQ scores above 1.5 indicate considerable levels of dis-
ability, shown to be the value above which progressive
damage to large joints (shoulder, elbow, hip, knee, ankle)
is expected to increase [15]. Therefore, the primary out-
come of interest in this analysis was HAQ score studied
as a binary outcome to indicate high (1.5) vs low (<1.5)
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HAQ at five years. HAQ at 10 years was investigated in
secondary analysis.
Statistical analysis
Five-year and 10-year HAQ
The statistical analysis was prespecified (Supplementary
Data S1, available at Rheumatology online) for HAQ out-
comes. Descriptive statistics were calculated for
patients with HAQ<1.5 and HAQ 1.5 values at five
and 10 years; medians and interquartile ranges (IQR) for
continuous variables, frequencies and proportions for
binary/ordinal. Odds ratios comparing the groups were
obtained using binary logistic regression models for
each covariate under consideration, fitting separate
models for five- and 10-year HAQ. Five-year outcomes
were not used in 10-year models, because only baseline
factors were of interest. Variables with a likelihood ratio
test P-value <0.2 were tested in multivariable analysis.
Models for five-year and 10-year HAQ were built using
forward selection based on clinical relevance and statis-
tical robustness to obtain odds ratios (ORs) and 95%
CIs. Age at onset, gender and RDCI were included a pri-
ori. Interaction testing was undertaken as appropriate to
determine inclusion of interaction terms and is described
in detail in Supplementary Data S2, available at
Rheumatology online. Once model building was com-
plete, multicollinearity between covariates was
assessed, excluding variables with centred variance in-
flation factors >10. After models were determined using
complete cases, multiple imputation by chained equa-
tions was used. All baseline variables in the complete
case model and HAQ outcomes were imputed. Baseline
and five-year values of clinical covariates (measured an-
nually) were included in the imputation model for the
five-year HAQ model, similarly baseline and 10-year val-
ues in the 10-year HAQ model, if available. Patients who
had died before year five/10, respectively, were
excluded from imputation models. Each model was per-
formed with 20 imputations. Continuous variables were
modelled using linear regression, binary using logistic
regression and ordinal using predictive mean matching.
Although two-sided P-values of <0.05 are referred to
as significant, a multiple testing correction was not
applied. Thus, P-values should be interpreted with cau-
tion and significant results seen as hypothesis-generat-
ing rather than confirmatory.
HAQ sensitivity analyses
In these analyses, five- and 10-year HAQ were used in
their continuous form. In addition, a binary RDCI variable
was formed, comparing patients with no comorbidities
(RDCI ¼ 0) to those with at least one (RDCI 1).
Supplementary analyses: Short-Form 36 health
questionnaire
To support the HAQ findings, the effect of baseline
comorbidity burden on health-related quality of life
(HRQoL) at five years was assessed, using the Short-
Form 36 Health Questionnaire (SF-36). Full details of the
methods used can be found in Supplementary Data S2,
available at Rheumatology online.
Results
The ERAS and ERAN cohorts recruited 2701 patients,
mean age 56.1 years and 66.9% female. Median time
from onset to first outpatient appointment was 6 months.
By year five, 1718 (63.4%) patients remained enrolled,
185 (6.8%) were known to have died and a further 798
(29.5%) were no longer in follow-up. At year 10, 820
(30.4%) were enrolled, 454 (16.8%) had died and 1427
(52.8%) were not in follow-up. Comparisons between
those still enrolled and those no longer followed up are
shown in Supplementary Tables S1 and S2, available at
Rheumatology online. Those remaining enrolled at five
years had median age of onset of 55.5 years (IQR 45–
65) compared with 62 (IQR 50–70) years for those no
longer followed up.
Five-year HAQ
Table 1 summarises baseline characteristics for patients
with HAQ<1.5 and HAQ 1.5 at five years, with scores
available for 1441 (83.9%) of those still in follow-up. A
higher age of onset was seen among the HAQ1.5
group (median 58, IQR 48–68 compared with median
55, IQR 43–63). A larger proportion of females had
HAQ1.5 (75.3% compared with 63.9% for HAQ<1.5).
More patients had a minority ethnic background with
HAQ1.5 (4.7% compared with 1.7%), although just 37
patients identified as belonging to a minority ethnic
group. A larger proportion of patients with HAQ1.5
were in the most deprived IMD quintile (15.8% com-
pared with 11.0%). Conversely, 28.8% of patients with
HAQ<1.5 were in the least deprived group compared
with 20.2% with HAQ 1.5.
More patients with HAQ1.5 had at least one comor-
bidity (with 18.2% having an RDCI score of 1 and
11.8% scoring 2, compared with the HAQ< 1.5 group,
where 13.5% had RDCI score of 1 and 9.9% had a
score of 2). The median RDCI score for both groups
was 0, although the IQR was slightly wider for
HAQ1.5 group. Each comorbidity category was slight-
ly more prevalent among the HAQ1.5 group.
Hypertension was the most common comorbidity, pre-
sent in 9.0% of patients with HAQ< 1.5 and 12.2% of
patients with HAQ1.5. Baseline HAQ was higher for
those with high five-year HAQ (median 1.5, IQR 1.00–
2.13 compared with 0.88, IQR 0.38–1.38) and DAS was
similarly elevated (5.30, IQR 4.47–6.08 compared with
4.51, IQR 3.68–5.49).
Results of univariable analyses are shown in
Supplementary Table S3, available at Rheumatology on-
line. Increased age at onset, being female, or of minority
ethnicity were associated with high HAQ, with P < 0.2.
The two least deprived IMD quintiles were associated
with a reduction in odds of HAQ 1.5. Several clinical
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HAQ 1.5, with P < 0.2. Notably, increasing baseline
HAQ was associated with a large increase in odds of
high five-year HAQ.
Multivariable analyses
Results of multivariable analyses are shown in Table 2.
No association was found between baseline RDCI and
HAQ 1.5 at five years in models fully adjusted for all
relevant covariates (OR 1.06, 95% CI: 0.90, 1.26).
Patients of minority ethnicity were at higher risk of high
five-year HAQ, but with a wide CI (OR 4.29, 95% CI:
2.13, 8.64). A strong association between baseline HAQ
and five-year HAQ was seen (OR 3.62, 95% CI: 3.01,
4.35). Increased age at onset, female gender, increased
onset to first outpatient time and seropositive status at
baseline were all associated with five-year HAQ1.5
scores. Worse deprivation levels were associated with
increased HAQ values, but including ethnicity attenuated
TABLE 1 Patient, comorbidity and disease characteristics according to elevated HAQ status
Five-year HAQ <1.5 Five-year HAQ 1.5 Ten-year HAQ <1.5 Ten-year HAQ 1.5
Total n (%) 1007 (69.9) 434 (30.1) 438 (60.9) 281 (39.1)
Sociodemographic
Age at onset (years): median
(IQR)
55 (45–63) 58 (48–68) 52 (43–61) 55 (45–64)
Female: n (%) 643 (63.9) 327 (75.3) 280 (63.9) 215 (76.5)
White ethnicity: n (%) 982 (98.3) 410 (95.3) 426 (98.6) 263 (94.9)
Ever smoked: n (%) 394 (48.1) 177 (50.1) 165 (41.9) 110 (44.0)
IMD quintiles: n (%)
1 (Most deprived) 97 (11.0) 61 (15.8) 40 (9.7) 57 (20.7)
2 123 (14.0) 68 (17.6) 48 (11.7) 50 (18.1)
3 211 (24.0) 101 (26.2) 87 (21.1) 64 (23.2)
4 196 (22.3) 78 (20.2) 91 (22.1) 43 (15.6)




0 (0–0) 0 (0–1) 0 (0–0) 0 (0–0)
Lung disease: n (%) 58 (5.8) 28 (6.5) 22 (5.0) 13 (4.6)
Heart attack, other CV,
stroke: n (%)
44 (4.4) 25 (5.8) 12 (2.7) 3 (1.1)
Fractures: n (%) 3 (0.3) 2 (0.5) 2 (0.5) 1 (0.4)
Depression: n (%) 15 (1.5) 10 (2.3) 4 (0.9) 6 (2.1)
Cancer: n (%) 13 (1.3) 10 (2.3) 4 (0.9) 4 (1.4)
Ulcer or stomach problem: n
(%)
24 (2.4) 18 (4.1) 8 (1.8) 8 (2.8)
Hypertension: n (%) 91 (9.0) 53 (12.2) 24 (5.5) 17 (6.0)
Diabetes: n (%) 16 (1.6) 9 (2.1) 8 (1.8) 6 (2.1)
Clinical measures
Onset to 1st appt: median
(IQR)
6 (4–12) 7 (4–12) 7 (4–12) 6 (4–12)
n¼1002 n¼431 n¼438 n¼281
1st appt to 1st DMARD: me-
dian (IQR)
2 (0–4) 1 (0–4) 2 (1–8) 2 (1–6)
n¼894 n¼415 n¼378 n¼268
HAQ: median (IQR) 0.88 (0.38–1.38) 1.50 (1.00–2.13) 0.75 (0.25–1.25) 1.38 (0.88–2.00)
n¼998 n¼428 n¼438 n¼281
DAS28: median (IQR) 4.51 (3.68–5.49) 5.30 (4.47–6.08) 4.46 (3.60–5.29) 5.11 (4.30–5.93)
n¼988 n¼427 n¼433 n¼279
BMI (kg/m2): median (IQR) 25.40 (22.80–28.40) 26.20 (23.05–29.76) 25.0 (22.6–27.4) 25.2 (22.5–28.7)
n¼920 n¼397 n¼400 n¼251
Erosions: n (%) 251 (25.5) 120 (28.2) 92 (21.2) 75 (27.6)
Nodules: n (%) 62 (6.2) 26 (6.0) 24 (5.5) 22 (7.8)
Haemoglobin (g/dl): median
(IQR)
12.8 (11.8–13.8) 12.6 (11.7–13.8) 12.8 (11.9–13.8) 12.5 (11.4–13.5)
n¼1001 n¼427 n¼434 n¼279
Seropositive: n (%) 702 (73.4) 327 (77.9) 315 (73.3) 209 (76.0)
ESR (mm/h): median (IQR) 30 (15–54) 36 (18–60) 30 (14–50) 40 (24–64)
n¼956 n¼416 n¼430 n¼279
1st appt to 1st DMARD: time (months) from first appointment to starting DMARD; DAS28: Disease Activity Score (28
count); IMD: Index of Multiple Deprivation; Onset to 1st appt: time (months) from symptom onset to first outpatient ap-
pointment; RDCI: Rheumatic Diseases Comorbidity Index.
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this association, suggesting a potential confounding ef-
fect. Evidence of association with ESR and odds of high
HAQ was found but with an extremely small effect size.
10-year HAQ
Table 1 compares sociodemographic, comorbidity and
disease characteristics, with HAQ scores recorded for
719 (87.7%) of those in follow up at year 10. Patients
with 10-year HAQ 1.5 scores were more likely to be
slightly older (median 55, IQR 45–64 compared with me-
dian 52, IQR 43–61), female (76.5% v 63.9%) and of mi-
nority ethnic origin (94.9% v 98.6%). Differences in
deprivation were more marked than at five years, 35.4%
of patients with HAQ<1.5 compared with just 22.5% of
those with HAQ 1.5 were in the least deprived quintile.
No notable differences were seen in RDCI or any
comorbidity component. Again, baseline HAQ was
higher for those with high 10-year HAQ (median 1.38,
IQR 0.88–2.00 compared with 0.75, IQR 0.25–1.25) and
similarly for baseline DAS28 (median 5.11, IQR 4.30–
5.93 compared with 4.46, IQR 3.60–5.29). More patients
with high 10-year HAQ scores had erosions (27.6% vs
21.2%) and nodules (7.8% vs 5.5%) at baseline.
Results of univariable analysis are shown in
Supplementary Table S3, available at Rheumatology on-
line. As with five-year HAQ, increased age at onset, fe-
male gender, minority ethnicity and more deprived IMD
quintiles were individually associated with high 10-year
HAQ scores, shown in Table 2. Baseline RDCI was not
associated with high 10-year HAQ scores, in contrast
with five-year HAQ. Among baseline clinical measures,
first appointment to first DMARD time, baseline HAQ,
baseline DAS28, BMI, haemoglobin and ESR remained
associated with P < 0.2. Although associated with five-
year HAQ, onset to first appointment time and being
seropositive were not associated with 10-year HAQ.
Conversely, presence of erosions at baseline were asso-
ciated with HAQ1.5 at 10 but not five years.
Multivariable analyses
Results of models fully adjusted for all covariates are
shown in Table 2. Baseline RDCI was not found to be
associated with increased odds of high 10-year HAQ
(OR 0.94, 95% CI: 0.73, 1.22). In contrast to the five-
year model, time from onset to first appointment, being
seropositive and ESR were not included. Worse depriv-
ation was associated with increased odds of 10-year
HAQ1.5 (OR 0.79, 95% CI: 0.69, 0.90). Baseline HAQ
remained strongly associated with high 10-year HAQ but
with a smaller magnitude than in the five-year model
(OR 2.47, 95% CI: 1.80, 3.41).
HAQ sensitivity analyses
Results are shown in Supplementary Table S4, available
at Rheumatology online. There remained no association
between baseline RDCI and baseline HAQ when consid-
ered binary and continuous respectively at either five
(0.03, 95% CI: 0.06, 0.12) or 10 years (0.01, 95% CI:
0.17, 0.18).
Supplementary analyses: Short-Form 36 health
questionnaire
Full results of this analysis are shown in Supplementary
Data S2, and model results presented in Supplementary
Table S5, both available at Rheumatology online. In
summary, there was no evidence of an association be-
tween RDCI at baseline and five-year SF-36, for either
the physical or mental scores.
TABLE 2 Sociodemographic and clinical factors associated with HAQ outcomes
5-year HAQ (n 5 2516) 10-year HAQ (n 5 2247)
Odds ratio (95% CI) Odds ratio (95% CI)
Baseline RDCI (continuous) 1.06 (0.90, 1.26)* 0.94 (0.73, 1.22)*
Age at onset 1.02 (1.01, 1.03) 1.02 (1.00, 1.03)
Gender (female) 1.48 (1.11, 1.97) 1.58 (1.10, 2.25)
Baseline HAQ 3.62 (3.01, 4.35) 2.47 (1.80, 3.41)
Minority ethnicity 4.29 (2.13, 8.64) 3.65 (1.55, 8.59)
Onset to 1st OPD (months) 1.03 (1.01, 1.05) a
IMD quintiles 0.95 (0.85, 1.05)** 0.79 (0.69, 0.90)
Seropositive 1.67 (1.21, 2.30) a
ESR (mm/h) 0.99 (0.99, 1.00) b
Variables tested in univariable analysis shown in Supplementary Table S2, available at Rheumatology online. IMD: index of
multiple deprivation; RDCI: rheumatic diseases comorbidity index. Variables tested in multivariable analyses: Five-year
HAQ: RDCI, age at onset, gender, HAQ, disease activity score, seropositive status, haemoglobin, ethnicity, IMD, time
(months) from symptom onset to first outpatient appointment, time (months) from first appointment to commencing
DMARD, BMI, ESR. Ten-year HAQ: RDCI and each component individually, age at onset, gender, HAQ, disease activity
score, presence of erosions, BMI, haemoglobin, ethnicity, IMD, time (months) from first appointment to commencing
DMARD. aNot selected in univariable analysis (P >0.2). bNot selected in multivariable analysis (P >0.05). Multivariable logis-
tic regression models; gender, age at onset and RDCI included a priori. *P >0.05 (not significant). **All P <0.02 except
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Discussion
This study shows that baseline comorbidity, measured
using the RDCI, is not significantly associated with high
HAQ at five or 10 years. In contrast, sociodemographic
factors (increased age at disease onset, female gender
and minority ethnicity) were significantly associated with
higher odds of HAQ 1.5 at five and 10 years. Worse
deprivation was associated with HAQ 1.5 at 10 years.
Previous studies have shown a high comorbidity bur-
den at diagnosis of RA, increasing over time [16, 17].
The recent work of England et al. [16] showed higher
incidence and poorer trajectory of multimorbidity in
patients with RA, particularly after symptom onset. Few
studies, however, have examined how comorbidities
are associated with RA disease outcomes in later
years. Recognising the importance of comorbidities,
we took the approach of adjusting for them in our mod-
els, allowing for effects of other variables to be seen,
possible only because of the wealth of data within
these cohorts.
In addition to functional outcome, this study consid-
ered patients likely to report poorer health-related qual-
ity of life (HRQoL) at five years, measured using the
Short-Form Health Survey (SF-36) [18], as described in
Supplementary Data S1, available at Rheumatology on-
line. HAQ and SF-36 were the focus of this study, rec-
ognising the importance of these patient-reported
outcomes (PROs) and the growing need to deliver more
tailored, holistic patient care that takes into account the
patient perspective [19]. The value of using these tools
is being increasingly recognised, as focus shifts towards
outcomes important to patients as well as clinicians.
This study is unique in two principal ways. Firstly, in
using two of the largest and longest longitudinal RA
cohorts, rich in comorbidity and other clinical and socio-
demographic data. Secondly, in attempting to study
both biological and non-biological factors using princi-
ples of syndemic theory to provide in-depth understand-
ing of associations between these factors and how they
could impact on physical function in RA. Evidence sug-
gests that comorbidities negatively impact on the
achievement of treat-to-target goals and act as a barrier
to optimal outcomes in RA [17, 20, 21]. This study goes
a step further, providing evidence that sociodemo-
graphic factors potentially play an additional role, be-
yond comorbidities, which should not be sidelined when
managing patients.
The focus of this study has been on using patient fea-
tures identified at the initial rheumatology appointment
to determine those more likely to have worse disease
outcome in later years. A previous study [22] found that
clinical data three months after onset was more inform-
ative, once treatment had begun. This work has shown
that, although clinical features can aid identification of
those patients for whom treatment failure is more likely,
sociodemographic factors, collected at baseline, can
also be helpful in guiding specific care pathways. These
may relate to drug therapy and or non-drug therapeutic
strategies such as more tailored physical therapy
(physiotherapy) especially in view of the outcome.
The link between joint damage and physical function
is well known and documented [23]. Although relevant
to the HAQ outcome, radiographic data were beyond
the scope of this study, which had a focus on sociode-
mographic and clinical factors and their potential role at
baseline.
Strengths of this study include the use of large, early
RA cohorts designed such that data could be collective-
ly analysed. The long study follow-up and treatment
according to best practice allow for useful, real-world in-
formation on RA treatment and outcomes. The richness
of data has resulted in meaningful analyses focussing
on parameters beyond those routinely reported in the lit-
erature, including sociodemographic factors. A study
limitation is the age of the cohorts, partly due to previ-
ous more conservative approaches to disease manage-
ment including lower use of biologic therapies,
especially in the context of comorbidities. Thus, general-
isability of study findings is limited. Additionally, few
patients identified with a minority ethnic heritage, so
their responses could not be meaningfully analysed to
represent different communities. Univariable analysis
showed a relationship between deprivation (IMD) and
HAQ1.5 outcome; in multivariable analysis this ceased
to exist once ethnicity was included at five years.
Deprivation and/or ethnicity appear to contribute to poor
HAQ outcome, with 28% of minority ethnicity compared
with 14% of white patients in the most deprived quintile
within these cohorts. However, limited sampling of these
subpopulations highlights an important avenue for future
study to better delineate these relationships, understand
these mechanisms and identify potentially modifiable
factors to redress health inequalities. A further limitation
is the number of hypotheses tested and lack of multiple
testing correction. It is possible that some significant
results are false positives, and results should be inter-
preted as exploratory rather than confirmatory.
In conclusion, this study found no association be-
tween baseline comorbidities and later functional out-
come. However, in models adjusting for comorbidities,
based on their importance and relevance on disease
outcomes in RA, sociodemographic factors play a role
in functional ability in the longer-term and should be
considered. These findings provide ground for risk strati-
fication in RA at first in-clinic patient review, enabling
the identification of patients at higher risk of functional
disability. Insights on the potential role of patient-
related, sociodemographic factors beyond traditional
disease measures such as high disease activity allows
for more holistic patient management and tailored inter-
vention to be undertaken.
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